In the present study, TMT-labeled mass spectrometry-based proteomics suggested that FGFR inhibition regulated glucose metabolism in a FGFRi-sensitive cancer cell line NCI-H1581 with FGFR1 amplification. Here, FGFR1 is linked to cancer.